US2012302587A1PendingUtilityA1
Rho-kinase inhibitors
Est. expiryJan 23, 2022(expired)· nominal 20-yr term from priority
A61P 43/00A61P 35/00A61P 9/10A61P 7/02A61P 9/12A61P 9/00A61P 25/28A61P 27/06A61P 25/00A61P 25/06A61P 19/10A61P 11/06A61P 15/00C07D 401/14C07D 401/12A61P 15/10A61P 19/08
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
Claims
exact text as granted — not AI-modified1 . A compound of the formula
2 . A method of treating an indication mediated by Rho-kinase, comprising administering a compound of claim 1 .
3 . A process according to claim 1 , wherein the host is a human.
4 . A method of treating hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, neuronal degeneration, spinal cord injury, cancer of the breast, colon, prostate, ovaries, brain or lung, thrombotic disorders, asthma, glaucoma, osteoporosis or erectile dysfunction, comprising administering to host in need thereof a compound according to claim 1 .
5 . A process according to claim 4 , wherein the host is a human.Join the waitlist — get patent alerts
Track US2012302587A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.